Download PDF
Thromb Haemost 1989; 62(04): 1088-1093
DOI: 10.1055/s-0038-1647123
Original Article
Fibrinolysis
Schattauer GmbH Stuttgart

Elimination of Native and Carbohydrate-Modified Tissue Plasminogen Activator in Rabbits

Monica Einarsson
The Research Department, Kabi, Stockholm, Sweden
,
Lena Häggroth
The Research Department, Kabi, Stockholm, Sweden
,
Christe Mattsson
The Research Department, Kabi, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 02 February 1989

Accepted after revision 15 September 1989

Publication Date:
24 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The elimination of native and carbohydrate-modified tissue type plasminogen activator (t-PA) after an i. v. bolus injection was studied in rabbits. t-PA with a low content of mannose (mant-PA) was obtained by treatment with α-mannosidase, which cleaves terminal mannose from the carbohydrate side chains of the molecule. About 50% of the total mannose was removed from the native t-PA.

Clearance of t-PA in rabbits was followed by measurements of both the fibrinolytic activity of the activators and the radioactivity of the iodine-labelled compounds. A biphasic mode of elimination of the fibrinolytic activity as well as of the radioactivity was found with both the native and the carbohydrate modified t-PA. The initial half-life (t½α) was the same, about 1.5 minutes, for both compounds, irrespective of method of analysis. The late half-life (t½β) was also the same, about 15 minutes, for both compounds. However, the β-elimination of native t-PA could only be determined accurately from radioactivity data in the dosages tested, i.e. up to 2 mg of t-PA. No dose dependency in the elimination pattern was observed.

In gel filtration experiments, with plasma from the rabbits, it was demonstrated that in addition to fibrinolytically active t-PA and man-t-PA, both fibrinolytically inactive high molecular weight complexes and low molecular weight degradation products of the activators were present in plasma after injection of the compounds.

The second phase of elimination .(β) was much more pronounced after mannosidase treatment of the t-PA. The proportion of molecules eliminated with a longer half-life was increased 6-7 times, from about 4% for native t-PA to about 25% for carbohydrate-modified t-PA.

Thus, a simple reduction of terminal mannose in the carbohydrate side chains of t-PA does not result in altered half-lives. However, a significantly greater proportion of molecules were eliminated in the late β-phase after the carbohydrate modification. The data also support our recent finding that the mannose receptor on the liver cells is at least in part responsible for the clearance of t-PA.

Keywords

Tissue plasminogen activator - Clearance - Carbohydrate - Mannose - Rabbit
 

  • References

  • 1 Collen D, Rijken DC, van Damme J, Billiau A. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo. Thromb Haemostas 1982; 48: 294-296
    PubMedGoogle Scholar
  • 2 Einarsson M, Brandt J, Kaplan L. Large-scale purification of human tissue-type plasminogen activator using monoclonal antibodies. Biochem Biophys Acta 1985; 831: 1-10
    CrossrefPubMedGoogle Scholar
  • 3 Pennica D, Holmes W, Kohr W, Harkins R, Vehar G, Ward C, Bennet W, Ylverton E, Seeburg P, Heyneker H, Goeddel D, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214-221
    CrossrefPubMedGoogle Scholar
  • 4 Mattsson C, Nyberg-Arrhenius V, Wallén P. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system. Thromb Res 1981; 21: 535-545
    CrossrefPubMedGoogle Scholar
  • 5 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activities and urokinase in vitro. Thromb Haemostas 1981; 45: 225-229
    PubMedGoogle Scholar
  • 6 Mattsson C, Nilsson S, Häggroth LD. Human extrinsic plasminogen activator. Fibrinolytic properties and neutralization in vivo Thromb Res 1983; 30: 91-100
    CrossrefPubMedGoogle Scholar
  • 7 ISIS-2 (Second International Study of Infarct Survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360
    PubMedGoogle Scholar
  • 8 Wilcox RG, Olsson CG, Skene AM, von der Lippe G, Jensen G, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET) Lancet 1988; 2: 525-530
    PubMedGoogle Scholar
  • 9 Sherry S. Recombinant tissue plasminogen activator (rt-PA). Is it the thrombolytic agent of choice for an evolving acute myocardial infarction Cardiology 1987; 59: 984-989
    PubMedGoogle Scholar
  • 10 Erbel R. Randomized trial of intravenous tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. 58th Scientific Session of the American Heart Association(1985), Nov 11-14, Abstract No. 891
    PubMedGoogle Scholar
  • 11 Carlin G, Einarsson M, Saldeen T. Tissue plasminogen activator effectively lyses intravascular fibrin deposits in the rat lung. In: Progress in Fibrinolysis. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (eds) Churchill-Livingstone; Edinburgh: 1983. Vol 6 pp 471-474
    Google Scholar
  • 12 Nilsson S, Einarsson M, Ekvärn S, Häggroth L, Mattsson C. Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. Thromb Res 1985; 39: 511-521
    CrossrefPubMedGoogle Scholar
  • 13 Korninger C, Stassen J-M, Roberts HR, Collen D. Turnover of human extrinsic tissue type plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
    PubMedGoogle Scholar
  • 14 Fuchs HE, Berger H, Pizzo SV. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65: 539-544
    PubMedGoogle Scholar
  • 15 Einarsson M, Smedsröd B, Pertoft H. Uptake and degradation of tissue plasminogen activator in rat liver. Thromb Haemostas 1988; 59: 474-479
    PubMedGoogle Scholar
  • 16 Smedsröd B, Einarsson M. Clearance of tissue plasminogen activator (t-PA) by galactose and mannose receptors in the liver. Thromb Haemostas 1990 63. (in press)
    PubMedGoogle Scholar
  • 17 Smedsröd B, Einarsson M, Pertoft H. Tissue plasminogen activator is endocytosed by mannose and galactose receptors of rat liver cells. Thromb Haemostas 1988; 59: 480-484
    PubMedGoogle Scholar
  • 18 Kuiper J, Otter M, Rijken DC, van Berkel TJ C. Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. J Biol Chem 1988; 263: 18220-18224
    PubMedGoogle Scholar
  • 19 Emeis JJ, van den Hoogen CM, Jense D. Hepatic clearance of tissue type plasminogen activator in rats. Thromb Haemostas 1985; 54: 661-664
    PubMedGoogle Scholar
  • 20 Rijken DC, Emeis JJ. Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. Biochem J 1986; 238: 643-646
    CrossrefPubMedGoogle Scholar
  • 21 Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol 1974; 41: 99-128
    PubMedGoogle Scholar
  • 22 Prieels J-P, Pizzo SV, Glasgow LR, Paulsson JC, Hill RL. Hepatic receptors that specifically binds oligosaccharides containing fucosyl α1-3N-acetylglucosamine linkages. Proc Natl Acad Sci USA 1987; 75: 2215-2219
    PubMedGoogle Scholar
  • 23 Schlesinger pH, Doebber JW, Handell BF, White R, Deschryver C, Rodman JS, Miller MJ, Stahl P. Plasma clearance of glycoproteins with terminal mannose and N-acetyl-glucosamine by liver nonparenchymal cells. Biochem J 1978; 176: 103-109
    CrossrefPubMedGoogle Scholar
  • 24 Rijken DC, Emeis JJ, Gerwig GJ. On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells. Thromb Haemostas 1985; 54: 788-791
    PubMedGoogle Scholar
  • 25 Pohl G, Kenne L, Nilsson B, Einarsson M. Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator. Eur J Biochem 1987; 170: 69-75
    CrossrefPubMedGoogle Scholar
  • 26 Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1, 3, 4, 6-tetrachloro-3 α,6α-diphenylglycouril. Biochem Biophys Res Commun 1978; 80: 849-857
    CrossrefPubMedGoogle Scholar
  • 27 Häggroth L, Mattsson C, Felding P, NilssonNilsson IM. Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women. Thromb Res 1986; 241: 739-749
    PubMedGoogle Scholar
  • 28 Norén I, Ramstriöim G, Wallén P. Fibrin plate method with reagents purified by affinity chromatography and its use for determination of fibrinolytic and other proteolytic activity in saliva, bile and plasma. Haemostasis 1975; 4: 110-124
    PubMedGoogle Scholar
  • 29 Beebe DP, Aronsson DL. Turnover of human tissue plasminogen activator (t-PA) in rabbits. Thromb Res 1986; 43: 663-674
    CrossrefPubMedGoogle Scholar
  • 30 Hotchkiss A, Refino CJ, Leonard CK, O’Connor JV, Crowley C, McCabe J, Tate K, Nakamura G, Powers D, Levinson A, Mohler M, Spellman MW. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemostas 1988; 60: 255-261
    PubMedGoogle Scholar